[1] 何明艳,朱碧琪,钟媛,等.2005-2013年中国女性乳腺癌发病及死亡趋势分析[J].中华疾病控制杂志, 2019, 23(1):10-14. [2] 顾秀瑛,郑荣寿,张思维,等.2000-2014年中国肿瘤登记地区前列腺癌发病趋势及年龄变化分析[J].中华预防医学杂志, 2018, 52(6):586-592. [3] ZHANG S, HUANG S X, ZHANG H, et al.Histo-and clinico-pathological analysis of a large series of triple-negative breast cancer in a single center in China:Evidences on necessity of histological subtyping and grading[J].Chin J Cancer Res, 2020, 32(5):580-595. [4] SCOTT E N, GOCHER A M, WORKMAN C J, et al.Regulatory T cells:barriers of immune infiltration into the tumor microenvironment[J].Front Immunol, 2021, 12:702726. [5] AVILA-PONCE DE LEÓN U, VÁZQUEZ-JIMÉNEZ A, MATADAMAS-GUZMAN M, et al.Transcriptional and microenvironmental landscape of macrophage transition in cancer:a Boolean analysis[J].Front Immunol, 2021, 12:642842. [6] LEE S Y, LEE S I, MIN B W, et al.Prognostic implication of systemic inflammatory markers in young patients with resectable colorectal cancer[J].Ann Surg Treat Res, 2021, 100(1):25-32. [7] TANG X X, CAO Y D, LIU J, et al.Diagnostic value of inflammatory factors in pathology of bladder cancer patients[J].Front Mol Biosci, 2020, 7:575483. [8] CHEN L, KONG X Y, YAN C R, et al.The research progress on the prognostic value of the common hematological parameters in peripheral venous blood in breast cancer[J].Onco Targets Ther, 2020, 13:1397-1412. [9] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志, 2011, 21(5):367-417. [10] 迟涛,尹明明,胡知齐.术前外周血多指标联合检测分析在乳腺癌诊断中应用价值[J].中华肿瘤防治杂志, 2020, 27(9):730-734, 739. [11] SUN H, YIN C Q, LIU Q, et al.Clinical significance of routine blood test-associated inflammatory index in breast cancer patients[J].Med Sci Monit, 2017, 23:5090-5095. [12] 袁茂林,韩琼,吴斌.外周血淋巴细胞和单核细胞比值与乳腺癌新辅助化疗疗效关联性[J].中华肿瘤防治杂志, 2020, 27(4):283-287. [13] EREN T, KARACIN C, UCAR G, et al.Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients[J].Medicine, 2020, 99(22):e20346. [14] CAZIUC A, SCHLANGER D, AMARINEI G, et al.Neutrophils-to-lymphocytes, lymphocytes to-monocytes and platelets-to-lymphocytes ratios-predictive biomarkers for response to neoadjuvant chemotherapy in breast cancer[J].J BUON, 2020, 25(1):182-187. [15] KIM J Y, JUNG E J, KIM J M, et al.Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis[J].BMC Cancer, 2020, 20(1):1206. [16] 胡赟宏,王铮元,崔嵘嵘,等.中性粒细胞/淋巴细胞比值与血小板/淋巴细胞比值对乳腺癌复发转移的预测价值及乳腺癌预后影响因素研究[J].中国全科医学, 2016, 19(30):3657-3661. [17] DUAN J W, PAN L L, YANG M.Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer:a meta-analysis[J].Medicine, 2018, 97(49):e13340. [18] 张艳秋,孙立柱.术前dNLR与三阴乳腺癌患者预后的关系[J].临床肿瘤学杂志, 2018, 23(9):830-834. [19] 赵佳琳,曹希,彭理,等.系统性炎症相关指标与乳腺癌临床病理及预后的相关性分析[J].南京医科大学学报:自然科学版, 2021, 41(1):74-81, 113. [20] CHO U, PARK H S, IM S Y, et al.Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer[J].PLoS One, 2018, 13(7):e0200936. [21] ZHOU L, MA S H, BALDE A I, et al.A retrospective propensity score matched study of the preoperative C-reactive protein to albumin ratio and prognosis in patients with resectable non-metastatic breast cancer[J].Med Sci Monit, 2019, 25:4342-4352. |